In combination with MSI status, versican and lumican are putative prognostic biomarkers that predict good outcome in stage II and III colon cancer patients, and in the latter also with respect to the effect of adjuvant chemotherapy. The gene discussed is LUM; the disease is malignant colon neoplasm.